Skip to content

Advertisement

  • Correction
  • Open Access

Correction to: PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse

  • 1, 2,
  • 1, 2,
  • 1, 2,
  • 1, 3,
  • 1, 2,
  • 1, 2,
  • 1, 2 and
  • 1, 2Email author
Contributed equally
Journal of Hematology & Oncology201811:37

https://doi.org/10.1186/s13045-018-0580-x

  • Received: 23 February 2018
  • Accepted: 23 February 2018
  • Published:

The original article was published in Journal of Hematology & Oncology 2018 11:16

Erratum

The original article [1] contained an error in Table 1 whereby the ‘Positive’ column in the ‘PD-L1’ Tumor type group of columns was mistakenly included at the beginning of the ‘PD-L2’ Tumor type group of columns.

This error has now been corrected. Furthermore, this error was not the fault of the authors, and was instead mistakenly carried forward by the production team that handled this article.

Table 1

Expression of PD-L1, PD-L2, and PD-1 in musculoskeletal tumors

Tumor

N

PD-L1

N (%)

PD-L2

N (%)

PD-1

N (%)

0

1+

2+

3+

Positive

0

1+

2+

3+

Positive

0

1+

2+

3+

Positive

Musculoskeletal tumor

234

179

35

10

10

55 (23.5%)

168

49

8

9

66 (28.2%)

185

37

5

7

49 (20.9%)

Giant cell tumor

14

4

1

2

7

10 (71.4%)

7

1

1

5

7 (50.0%)

6

1

2

5

8 (57.1%)

Osteosarcoma

62

40

17

3

2

22 (35.5%)

36

21

3

2

26 (41.9%)

45

15

1

1

17 (27.4%)

Synovial sarcoma

127

107

16

3

1

20 (15.7%)

101

22

2

2

26 (20.5%)

103

21

2

1

24 (18.9%)

Chondrosarcoma

31

28

1

2

0

3 (9.7%)

24

5

2

0

7 (22.6%)

31

0

0

0

0

Conventional chondrosarcoma

27

27

0

0

0

0

21

4

2

0

6 (22.2%)

27

0

0

0

0

Dedifferentiated chondrosarcoma

4

1

1

2

0

3 (75.0%)

3

1

0

0

1 (25.0%)

4

0

0

0

0

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Musculoskeletal Tumor Center, Peking University People’s Hospital, No. 11 Xizhimen South Street, Beijing, 100044, People’s Republic of China
(2)
Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People’s Republic of China
(3)
Department of Pathology, Peking University People’s Hospital, Beijing, People’s Republic of China

Reference

  1. Zheng B. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol. 2018;11:16.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

Advertisement